NurExone Secures South Korean Patent for ExoPTEN, Expanding Global IP Footprint

Event summary

  • NurExone received a Notice of Patent Grant from South Korea's Ministry of Intellectual Property for its ExoPTEN technology on May 19, 2026.
  • The patent covers exosome-based drug delivery systems targeting nerve injury treatments.
  • NurExone now holds ExoPTEN patents in the U.S., Japan, Israel, Russia, and South Korea, with pending applications in multiple jurisdictions.
  • The company's broader patent portfolio includes EV production technologies in Australia, the U.S., and Israel.

The big picture

NurExone's South Korean patent grant strengthens its global IP strategy, which is critical for protecting its exosome-based therapies in key markets. This move aligns with broader industry trends where biotech firms are aggressively securing international patents to support clinical development and commercialization. The company's focus on nerve injury treatments positions it in a niche but growing segment of regenerative medicine, where IP protection is paramount for securing partnerships and investment.

What we're watching

IP Protection Strategy
How NurExone will leverage this patent to strengthen its market position in Asia, particularly in South Korea's growing biotech sector.
Clinical Development
Whether the expanded IP portfolio will accelerate ExoPTEN's path to clinical trials and commercialization in key markets.
Competitive Dynamics
The pace at which NurExone can secure additional patents in pending jurisdictions, particularly in the EU and China, to maintain its competitive edge.